Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

King/Meridian EpiPen

This article was originally published in The Gray Sheet

  • News

Executive Summary

Pharmaceutical auto-injector devices for allergic reactions, made by Meridian Medical Technologies, are cited as a key draw of $247.8 mil. acquisition by King Pharmaceuticals. King will pay $44.50 per share in cash for the firm, a 17% premium to its Oct. 18 close of $38.15. In addition to gaining EpiPen, drug maker King plans to leverage Meridian's NDA-approved auto-injector technology in the area of homeland security. Meridian currently offers the technology to the military for use with a nerve gas antidote, as well as auto-injectors filled with morphine, diazepam and lidocaine. The Columbia, Maryland firm reported net income of $9.3 mil. for the year ended July 31 on revenues of $82.4 mil., including $4.6 mil. in sales of telemedicine and ECG devices...

Table

View full table

Tags:
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT017371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By